Phase 2 SCLC Trial Tests FHD-286 SMARCA4/2 Inhibitor
Summary
A Phase 2 clinical trial (NCT07551635) has been registered on ClinicalTrials.gov evaluating FHD-286, a SMARCA4/2 ATPase inhibitor targeting the SWI/SNF chromatin remodeling complex, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. The single-arm trial will administer FHD-286 orally once daily in 21-day cycles, with objective response rate as the primary endpoint.
“This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 2 clinical trial (NCT07551635) has been registered on ClinicalTrials.gov evaluating FHD-286, a SMARCA4/2 ATPase inhibitor targeting the SWI/SNF chromatin remodeling complex, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. The trial is single-arm with once-daily oral dosing in 21-day cycles.
Oncology researchers and patients with POU2F3-expressing small cell lung cancer may identify this trial as a potential enrollment option. Drug developers in the targeted therapy space may monitor this study for early efficacy signals in this specific biomarker-defined population.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Phase 2 NCT07551635 Kind: PHASE2 Apr 27, 2026
Abstract
This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population.
The names of the study drug involved in this study is:
• FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)
Conditions: Small Cell Lung Cancer
Interventions: FHD-286
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.